83 results about "Subcutaneous injection" patented technology

Most therapeutic treatments require dose adjustment after initial administration. Dosage adjustment is crucial to ensuring optimal safety and efficacy characteristics of the treatment. Gene therapy is inherently limited by the inability to adjust the dose after initial administration. This invention describes a genetic element capable of dose adjustment after the initial administration of gene therapy. The realization of dose adjustment allows for the replacement of multiple subcutaneous protein injection regimens with single-injection gene therapy, thereby improving pharmacokinetics, safety / efficacy characteristics, medication adherence, and reducing healthcare costs.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition comprising the same for subcutaneous administration, and a method for preparing the same. In the case of using the preparation method of the present invention, nanoparticles comprising sirolimus and albumin having excellent stability of particle size distribution can be prepared, the prepared nanoparticles can be prepared as a pharmaceutical composition suitable for subcutaneous injection, and the increase in administration dose and the convenience of administration can be improved.

This utility model discloses a portable syringe plunger auxiliary device, comprising: a base and a power supply module. A syringe holder and an electric plunger are mounted on the base; the syringe holder is configured to engage an injection syringe; the electric plunger is positioned such that its output shaft extends toward the syringe holder, and the electric plunger pushes the piston handle of the injection syringe engaged in the syringe holder toward the needle tip of the injection syringe; the power supply module is installed within the base and electrically connected to the electric plunger through a first power supply circuit, and the power supply module supplies power to the electric plunger. This utility model helps nursing personnel achieve a stable and uniform injection operation over a long period during subcutaneous injections.

1. The name of the design product: insulin injection simulation artificial skin. 2. The use of the design product: the product is mainly used to demonstrate injection site selection and injection process in subcutaneous injection education process. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: perspective view. 5. The design for which protection is sought contains color. 6. The back of the design product is a part that is not easy to see or cannot be seen during use, and the rear view is omitted.

The invention discloses near-infrared thermal molecules, nano particles, injectable near-infrared thermal hydrogel and application of the injectable near-infrared thermal hydrogel in preparation of anti-obesity drugs. The structural formula of the near-infrared photothermal molecule is shown in the specification. According to the invention, molecular structure design is carried out to obtain near-infrared thermal molecules with strong near-infrared absorption, bright near-infrared two-region fluorescence emission and high photo-thermal stability; near-infrared photothermal molecules are packaged into spherical nanoparticles by using an amphiphilic polymer through a nanoprecipitation method, the spherical nanoparticles are further mixed with a temperature-sensitive matrix material to prepare the near-infrared photothermal hydrogel capable of being subcutaneously injected, after near-infrared irradiation, adipocyte apoptosis can be remarkably induced, meanwhile, white fat is promoted to be converted into beige fat, and the effect of preparing the near-infrared photothermal hydrogel is achieved. The efficient anti-obesity effect is achieved; and hydrogel degradation, medicament distribution and treatment processes can be tracked in real time through near-infrared two-region fluorescence imaging, so that the controllability and accuracy of treatment are improved. The whole system shows good biocompatibility, and has outstanding application potential in the anti-obesity field.

Provided herein are ketamine formulations for subcutaneous injection, in particular subcutaneous formulations of ketamine useful for the treatment of various diseases and disorders. The subcutaneous ketamine preparation provided by the invention reduces stimulation and pain of an injection site.

The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

The present disclosure provides a storage-stable solid composition comprising a biopharmaceutical agent and a polyacrylamide-based copolymer. The present inventors have demonstrated that particular polyacrylamide-based copolymers can be used as stabilizing excipients in lyophilized formulations of biopharmaceutical agents. Methods of reconstituting and using the compositions are also provided, including methods of administering the reconstituted compositions to a human subject in need thereof by injection, e.g., subcutaneous injection.

The present disclosure relates to a pharmaceutical formulation suitable for sublingual administration for use in the treatment of obesity, type II diabetes, or related diseases. The pharmaceutical formula comprises 5 to 10 milligrams of glucagon-like peptide-1 receptor agonist peptide (GLP-1 RA-P) which is dissolved in 1.5 to 2.0 milliliters of a buffer solution, and the pH (Potential of Hydrogen) value of the pharmaceutical formula is 5.5 to 7.5. The disclosure also discloses a method for treating obesity, type II diabetes, or related diseases. The method comprises administering the pharmaceutical formulation of the present disclosure to a subject in a sublingual administration, and allowing the pharmaceutical formulation to be continuously located sublingually of the subject for 5-10 minutes, where the pharmaceutical formulation has a bioavailability for GLP-1 RA-P of 2-10% compared to the administration to the subject through subcutaneous injection.

A method for subcutaneously administering an isolated anti-CD38 antibody at low doses is disclosed. This method provides effective treatment for autoimmune diseases, including hematological disorders, and cancer. A unit dosage form of the anti-CD38 antibody is also disclosed. [Selected Figure] Figure 1

This invention provides an improved formulation and administration method of an FcRn inhibitor for use in the treatment of autoimmune diseases. [Solution] An aqueous formulation containing approximately 100-300 mg / mL of an FcRn antagonist, 20-60 mM histidine / histidine HCl, 0-70 mM sucrose, 0-150 mM NaCl, 0-250 mM arginine HCl, 0%-0.05% (w / v) polysorbate 20 or polysorbate 80, and 0-15 mM L-methionine. The aqueous formulation has a pH of 6.0-6.5, and the FcRn antagonist consists of a variant Fc region, which consists of two Fc domains that form a homodimer.

Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.

The present disclosure provides, among other things, methods and compositions for the oral administration of polypeptides. Many polypeptides are typically administered in liquid solutions by intravenous or subcutaneous injection. The present disclosure provides methods and compositions that include a polypeptide formulation, e.g., truffle, tablet, globule, candy, capsule formulation suitable for oral administration, where the formulation includes an amorphous polypeptide composition or a crystallized polypeptide composition and a pharmaceutically acceptable carrier.

The utility model provides a subcutaneous injection device which comprises a needle cylinder seat, a push rod driving seat, a main machine and an angle seat and can be used for long-time subcutaneous injection, when the device is used, after the device is fixed on a thigh by means of the angle seat, automatic needle feeding and automatic pushing can be achieved by means of the angle seat, and only a corresponding motor needs to be started. According to the automatic subcutaneous injection device, subcutaneous injection can be automatically carried out according to time and speed, the two hands of nursing personnel can be liberated, clinical service can be more effectively achieved, the operation burden of medical personnel is relieved, the set angle and speed can be always kept in the needle inserting and medicine pushing process, the needle inserting and medicine pushing process can be accurately carried out according to setting of electric equipment, and the subcutaneous injection quality can be better ensured.

The present invention relates to a device (100) for subcutaneous injection of gas, particularly carbon dioxide (CO2), and more particularly to a cosmetic device, comprising a gas reservoir (10) in fluid communication with a hollow microneedle (4) via a distribution line (20). The device includes a purging system (22) for removing residual gas present in the microneedle.

The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorders, such as a non-Hodgkin's lymphoma (NHL); e.g., an aggressive NHL or a relapsed and / or refractory NHL). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.

The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.

The objective invention provides a parenteral composition of semaglutide or a pharmaceutically acceptable salt thereof for subcutaneous administration, having a strength and composition such that it can be administered multiple times from single article of manufacture, for use in treating type 2 diabetes mellitus and for weight loss, thereby providing benefit to the patient.

The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps:(a) topical application or subcutaneous injection of said composition to an area of the skin of said patient,(b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and(c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizeras well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 1000 mg to about 1800 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 500 mg to about 900 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

The invention provides a construction method of a mouse dry eye model, and belongs to the technical field of animal model construction. The construction method comprises the following steps: dripping a benzalkonium chloride solution into the ocular surface of a mouse, injecting a scopolamine solution into the mouse in a subcutaneous manner, placing the mouse in a dry environment, and modeling to obtain the mouse dry eye model. The formation of the mouse dry eye model is induced through a dry environment and a compound condition of benzalkonium chloride and scopolamine. According to the mouse dry eye model, the tear secretion amount is remarkably reduced, ocular surface inflammation occurs, and the dry eye syndrome can be well simulated. The model can be used for screening medicines for treating the xerophthalmia and carrying out other researches on the xerophthalmia, and has a good application prospect.

The utility model relates to an insulin pen capable of preventing pricking injury. The insulin pen comprises a needle head and a needle cylinder, an annular circular truncated cone is arranged at the lower end of the needle head, and a clamping tenon is arranged on the edge of the circular truncated cone; a cylindrical connecting device is arranged at the end of the needle cylinder, a limiting hole is formed in the connecting device, and a springback device is arranged in the connecting device. The lower end of the needle head is arranged in the cylindrical connecting device in a sleeving manner; and the lower end of the needle head is clamped in the limiting hole of the cylindrical connecting device through a tenon. When the needle head is installed, the end opening, provided with the circular truncated cone, of the needle head is aligned with and inserted into the end, provided with the connecting device, of the needle head, so that the clamping tenon can enter the limiting hole, the needle head and the needle cylinder can be fixed, and a user conducts subcutaneous injection through the device to feed insulin into the body; when the needle head is detached, the needle head can be detached only by pressing the needle head towards the needle cylinder and rotating the needle head towards the two sides. When the device is used, the dismounting is obviously very simple, the safety is high, and the situations that the needle head stabs a user and needs to be screwed by hands are avoided.

The present invention relates to a pharmaceutical preparation for subcutaneous administration, the preparation comprising: an antibody-drug conjugate (ADC); and native human recombinant hyaluronidase PH20.

The present invention relates to a composition for manufacturing a microarray comprising semaglutide as an active ingredient, a microarray manufactured using the composition, a method for manufacturing the microarray, and an assembly comprising the microarray. The microarray of the present invention has excellent stability allowing storage and transportation at room temperature and exhibits pharmacokinetic characteristics similar to those of subcutaneous injection.

The invention relates to a metal polyphenol nano composite material and a preparation method and application thereof, the metal polyphenol nano composite material comprises a tumor antigen and a metal polyphenol network, and the tumor antigen is doped in the metal polyphenol network to form the nano composite material. According to the invention, after the nano-drug is subjected to intratumor administration, laser is applied, so that chemical kinetics / mild photo-thermal / immune combined treatment on tumors can be realized. In addition, the nano vaccine shows a corresponding tumor generation prevention effect after subcutaneous injection, and has potential clinical application value.

The present invention relates to a method of TNF-α related disease by subcutaneously administering an antibody binding to TNF-α (anti-TNF-α antibody). A treatment method, composition, kit or use according to the present invention reduces the time for administration and the time for patients to stay in hospitals, thereby improving patient convenience and the quality of life of the patient. This provides the advantage of improving the patient's satisfaction.